Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Irvine Scientific Launches BalanCD™ CHO SLX A Culture Media Developed for the Selexis SURE CHO-M Cell Line



Irvine Scientific Launches BalanCD™ CHO SLX A Culture Media Developed for the
                         Selexis SURE CHO-M Cell Line

The New Media Improves SURE CHO-M Productivity

PR Newswire

GENEVA, June 6, 2012

GENEVA, June 6, 2012 /PRNewswire/ -- Selexis SA, a global life sciences
company for drug discovery, cell line development and scale-up to
manufacturing of therapeutic proteins, announced today the launch and
availability of a chemically-defined, animal-component free media designed to
greatly increase the productivity and viability of Selexis SURE CHO-M cell
lines. This product, developed in collaboration with Irvine Scientific is
designed exclusively for Selexis. The new formulation is called BalanCD™ CHO
SLX A, improves cell viability, increases productivity during pilot and
process development, and maintains consistency between runs. These and other
benefits should facilitate scale-up in bioreactors.

Irvine Scientific, using its Rational Culture Media Design™ approach, worked
with researchers at Selexis to develop a custom formulation that allows rapid
optimization of processes where the SUREtechnology Platform™ is being
evaluated or used.

"Our customers will be very satisfied with the outcome of this collaboration
with Irvine Scientific, a company known for innovative, high production CHO
formulations," said Igor Fisch, PhD, CEO of Selexis SA. "In combination with
our SUREtechnology™ Platform, BalanCD™ CHO SLX A is an important new resource
to further assist our customers in speeding drug development while reducing
production costs and risks." 

"We are very pleased to be able to offer an optimized media for the Selexis
SUREtechnology™ Platform, an industry standard for cell line development,"
said Jessie Ni, PhD, CSO of Irvine Scientific. "BalanCD™ CHO SLX A represents
an important expansion of Irvine Scientific's portfolio of chemically-defined
media. But more importantly provides a more complete solution to customers
that need to increase the speed with which they evaluate cell lines, the
quality of proteins developed, and optimization of process development. The
collaboration with Selexis can provide all these benefits to customers using
CHO platforms for their protein therapeutics."

To learn more about BalanCD™ CHO SLX A™, please contact Armelle Gaussin, PhD
at armelle.gaussin@selexis.com, or TMrequest@irvinesci.com.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science
company with innovative technologies and world-class expert services for drug
discovery, cell line development and scale-up to manufacturing of therapeutic
proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic
Elements™ -- novel DNA-based elements that control the dynamic organization of
chromatin within all mammalian cells and allow for higher and more stable
expression of recombinant proteins. Selexis has generated over 1,300 cell
lines being used in a variety of programs from drug discovery to late-stage
clinical trials. The Company anticipates three products manufactured from cell
lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information:
- Visit http://www.selexis.com
- Follow us on Twitter @selexisSA
- Become a fan at www.facebook.com/SelexisSA

About Irvine Scientific
Irvine Scientific, a member of JX Holdings group, is a worldwide leader in the
design, manufacture and distribution of medical devices, including Industrial
Cell Culture, Cytogenetic, Assisted Reproductive Technology (ART) and
Specialty Media products. Irvine Scientific is a worldwide media provider that
is regulated and adheres to both ISO and FDA regulations with dual
manufacturing facilities in California, USA and Tokyo, Japan. Irvine
Scientific is a large scale producer of advanced quality cell culture media
for the industrial bioprocess, medical, and diagnostic markets. The company's
extensive experience in the design of culture media, compliance with ISO and
FDA regulations for class II / III medical devices, industrial scale
manufacturing capacity, provides its customers with unique capabilities and
support. Irvine Scientific delivers products worldwide to biopharmaceutical
industry, research and medical laboratory communities.

For more information:
- Visit http://www.irvinesci.com
- Follow us on LinkedIn at
http://www.linkedin.com/company/irvine-scientific?trk=tabs_biz_home

Contact: Robert Meister, +1-602-953-1716, robert.meister@selexis.com

SOURCE Selexis SA
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement